Recent Updates
Recently added Catalysts

Cefdinir

Phase 1

Healthy | Small molecule | Other |Teva Pharmaceutical Industries Limited|Last Updated: Aug 20, 2024

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedACTIVE_CONTROLLED
Total Trials4
Total Enrollment128

FDA Designations

No designations recorded

Clinical trial landscape

Cefdinir · 4 trials · 1 indication

Phase 1 4
NCT00834535Cefdinir Capsules 300 mg, Non-fastingHealthy
COMPLETED32 Analytics
NCT00835484Cefdinir Capsules 300 mg, FastingHealthy
COMPLETED32 Analytics
NCT00835549Cefdinir for Oral Suspension 250 mg/5mL, Non-fastingHealthy
COMPLETED32 Analytics
NCT00834574Cefdinir for Oral Suspension 250 mg/5mL, FastingHealthy
COMPLETED32 Analytics
PHASE1COMPLETED
Cefdinir Capsules 300 mg, Non-fasting
HealthyUnlock trial analytics
PHASE1COMPLETED
Cefdinir Capsules 300 mg, Fasting
HealthyUnlock trial analytics
PHASE1COMPLETED
Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting
HealthyUnlock trial analytics
PHASE1COMPLETED
Cefdinir for Oral Suspension 250 mg/5mL, Fasting
HealthyUnlock trial analytics

Study Endpoints

Primary Endpoints

Cmax (Maximum Observed Concentration)
Blood samples collected over a 14 hour period.

Bioequivalence based on Cmax.

AUC0-t (Area Under the Concentration-time Curve From Time Zero to Time of Last Measurable Concentration)
Blood samples collected over a 14 hour period.

Bioequivalence based on AUC0-t.

AUC0-inf (Area Under the Concentration-time Curve From Time Zero to Infinity)
Blood samples collected over a 14 hour period.

Bioequivalence based on AUC0-inf.

Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingNONE
ModelCROSSOVER
PurposeOTHER

Treatment Arms

ArmTypeDescription
1EXPERIMENTAL -
2ACTIVE_COMPARATOR -

Interventions

NameTypeDescription
Cefdinir Capsules 300 mgDRUG1 x 300 mg, single-dose non-fasting
OMNICEF® Capsule 300 mgDRUG1 x 300 mg, single-dose non-fasting
OMNICEF® 300 mgDRUG1 x 300 mg, single-dose fasting
Cefdinir for oral suspension 250 mg/5mLDRUG1 x 250 mg/5mL, single-dose non-fasting
OMNICEF® for oral suspension 250 mg/5mLDRUG1 x 250 mg/5mL, single-dose non-fasting
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to N/A
SexALL
Healthy VolunteersYes
Study Sites2

Inclusion Criteria: * Screening Demographics: All subjects selected for this study will be healthy men and women 18 years of age or older at the time of dosing. the subject's body mass index (BMI) should be 19 kg/m² - 30 kg/m², inclusive. * Screening procedures: Each subject will complete the scree...

Countries:United States
Unlock Eligibility Criteria

Frequently asked questions about Cefdinir

What is Cefdinir used for?

Cefdinir is an investigational small molecule being studied in healthy volunteers. It is being developed by Teva Pharmaceutical Industries Limited (TEVA). The drug is currently in Phase 1 clinical development, with all completed trials conducted in the United States.

Who makes Cefdinir?

Cefdinir is being developed by Teva Pharmaceutical Industries Limited, which trades under the ticker TEVA. The company is conducting Phase 1 clinical trials of the drug in healthy volunteers in the United States.

What phase is Cefdinir in?

Cefdinir is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. All four clinical trials for Cefdinir have been completed, with a total enrollment of 128 participants.

What clinical trials is Cefdinir in?

Cefdinir has been studied in four completed Phase 1 clinical trials: NCT00834535 (Cefdinir Capsules 300 mg, Non-fasting), NCT00834574 (Cefdinir for Oral Suspension 250 mg/5mL, Fasting), NCT00835484 (Cefdinir Capsules 300 mg, Fasting), and NCT00835549 (Cefdinir for Oral Suspension 250 mg/5mL, Non-fasting). Each trial enrolled 32 healthy volunteers.

Is Cefdinir a randomized controlled trial drug?

Yes, the clinical trials for Cefdinir are randomized and active-controlled. They are not double-blind and do not use biomarker selection. The trials enrolled healthy volunteers aged 18 years and older, with both males and females included.